Xlife Sciences AG (SWX:XLS)
Switzerland · Delayed Price · Currency is CHF 8.50
-0.86 (-9.19%)
At close: Oct 22, 2026
Xlife Sciences AG Revenue
Xlife Sciences AG had revenue of 476.23K CHF in the half year ending June 30, 2026, with 36.14% growth. This brings the company's total for the last twelve months to 397.23K, down -52.68% year-over-year. In the year 2025, Xlife Sciences AG had annual revenue of 275.31K, down -67.02%. That makes Xlife Sciences AG the 44,565th largest company in the world by revenue and 201st in Switzerland.
Revenue (ttm)
397.23K
Revenue Growth
-52.68%
P/S Ratio
135.89
Revenue / Employee
19.86K
Employees
20
Market Cap
49.02M
Revenue by Segment
- Technology Platforms 148.96K 54.1%
- Unallocated 126.36K 45.9%
Fiscal year ended Dec 31, 2025 See the full Xlife Sciences AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 275.31K | -559.57K | -67.02% |
| Dec 31, 2024 | 834.88K | -153.56K | -15.54% |
| Dec 31, 2023 | 988.44K | -39.54K | -3.85% |
| Dec 31, 2022 | 1.03M | 221.91K | 27.53% |
| Dec 31, 2021 | 806.07K | 409.26K | 103.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bachem Holding AG | 708.53M |
| Basilea Pharmaceutica AG | 247.42M |
| Idorsia | 199.71M |
| Santhera Pharmaceuticals Holding AG | 101.50M |
| Newron Pharmaceuticals | 9.62M |
| BioVersys AG | 4.62M |
| MindMaze Therapeutics Holding | 1.20M |
| Molecular Partners AG | 681.00K |